Jeff Carroll, Ph.D., inherited a gene that will eventually lead to symptoms of Huntington’s Disease. Alongside researching this debilitating disease as an Associate Professor of Neurology at the University of Washington, he’s a Scientific Advisor for n-Lorem and member of the Access to Treatment Committee (ATTC) that helps screen and assess submitted patient applications.
On This Episode We Discuss:
<ul><li>2:45 Joining the Amy on a whim </li>
<li>4:30 Serving in Kosovo and Germany</li>
<li>6:00 Learning that his mother was diagnosed with Huntington’s disease (HD)</li>
<li>10:25 Seeking information and diving into the world of Biology and HD</li>
<li>14:52 Deciding to have children when there was a chance that they’d inherit the disease and utilizing preimplantation genetic diagnosis (PGD)</li>
<li>18:30 Watching Ionis make initial progress on an ASO for Huntington’s disease</li>
<li>23:10 How Jeff became involved with n-Lorem</li>
<li>27:30 Most important things Jeff has learned during his role at n-Lorem</li>
<li>30:38 Helping people is motivating</li>
<li>32:11 Nano-rare patients teach us a lot about science</li>
<li>33:57 Jeff expects to receive an ASO treatment one day</li>
<li>35:22 n-Lorem is on your side </li>
</ul>

Jeff Carroll, Ph.D., inherited a gene that will eventually lead to symptoms of Huntington’s Disease. Alongside researching this debilitating disease as an Associate Professor of Neurology at the University of Washington, he’s a Scientific Advisor for n-Lorem and member of the Access to Treatment Committee (ATTC) that helps screen and assess submitted patient applications. On This Episode We Discuss: 2:45 Joining the Amy on a whim 4:30 Serving in Kosovo and Germany 6:00 Learning that his mother was diagnosed with Huntington’s disease (HD) 10:25 Seeking information and diving into the world of Biology and HD 14:52 Deciding to have children when there was a chance that they’d inherit the disease and utilizing preimplantation genetic diagnosis (PGD) 18:30 Watching Ionis make initial progress on an ASO for Huntington’s disease 23:10 How Jeff became involved with n-Lorem 27:30 Most important things Jeff has learned during his role at n-Lorem 30:38 Helping people is motivating 32:11 Nano-rare patients teach us a lot about science 33:57 Jeff expects to receive an ASO treatment one day 35:22 n-Lorem is on your side

Inheriting Huntington’s Disease and Aspiring to Prolong Lives with Jeff Carroll

Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life. 

n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. 

The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crroke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Kim Butler, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.

Science

Medicine

Health & Fitness

Education

Life Sciences

Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life. n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crroke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Kim Butler, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.

Share Inheriting Huntington’s Disease and Aspiring to Prolong Lives with Jeff Carroll

Sign up to save your podcasts

Inheriting Huntington’s Disease and Aspiring to Prolong Lives with Jeff Carroll

Inheriting Huntington’s Disease and Aspiring to Prolong Lives with Jeff Carroll

More shows like Patient Empowerment Program: A Rare Disease Podcast

This American Life

Embedded

The Daily

Crime Junkie

The Readout Loud

The Weekly Show with Jon Stewart

BioSpace